Literature DB >> 33817311

miR-338-3p inhibits cell growth, invasion, and EMT process in neuroblastoma through targeting MMP-2.

Haibin Yuan1, Fengli Liu1, Tongsheng Ma1, Zhandong Zeng1, Ning Zhang1.   

Abstract

This study aimed to explore the regulatory mechanisms of miR-338-3p and matrix metalloproteinase-2 (MMP-2) in neuroblastoma. Putative target interaction regions of miR-338-3p on MMP-2 were predicted by miRcode and miRbase bioinformatics tools. Relative expression of miRNA-338-3p and MMP-2 in neuroblastoma tissues and GI-LI-N and SK-N-SH cells was determined by reverse transcription polymerase chain reaction experiment. Furthermore, the cell proliferation was determined by Cell Counting Kit-8 assay, the cell apoptosis rate was analyzed by flow cytometry assay, and the cell invasion was evaluated by transwell assay. miR-338-3p expression was downregulated, whereas MMP-2 expression was upregulated in metastasis tissue site compared to that in primary tissue site in total. Furthermore, miR-338-3p overexpression suppressed proliferation, invasion, and epithelial-mesenchymal transition (EMT) of neuroblastoma cells but promoted apoptosis, and the knockdown of MMP-2 triggered similar effects. Furthermore, MMP-2 was directly targeted by miR-338-3p, and overexpression of MMP-2 rescued the inhibitory effects of miR-338-3p on human neuroblastoma cell progression. Collectively, these data demonstrated that miR-338-3p could suppress cell growth, invasion, and EMT pathway and induce apoptosis in neuroblastoma cells by targeting MMP-2. MiR-338-3p sponged MMP-2 to regulate the PI3K/AKT pathway in human neuroblastoma cells.
© 2021 Haibin Yuan et al., published by De Gruyter.

Entities:  

Keywords:  EMT pathway; MMP-2; PI3K/AKT signaling; miR-338-3p; neuroblastoma

Year:  2021        PMID: 33817311      PMCID: PMC7968531          DOI: 10.1515/biol-2021-0013

Source DB:  PubMed          Journal:  Open Life Sci        ISSN: 2391-5412            Impact factor:   0.938


  36 in total

Review 1.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.

Authors:  Robert Visse; Hideaki Nagase
Journal:  Circ Res       Date:  2003-05-02       Impact factor: 17.367

Review 2.  Current management of neuroblastoma and future direction.

Authors:  Elizabeth R Pastor; Shaker A Mousa
Journal:  Crit Rev Oncol Hematol       Date:  2019-04-01       Impact factor: 6.312

3.  MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2.

Authors:  Peng Zhang; Guoguang Shao; Xingyu Lin; Yunpeng Liu; Zhiguang Yang
Journal:  Am J Cancer Res       Date:  2017-01-01       Impact factor: 6.166

Review 4.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

Authors:  Navin R Pinto; Mark A Applebaum; Samuel L Volchenboum; Katherine K Matthay; Wendy B London; Peter F Ambros; Akira Nakagawara; Frank Berthold; Gudrun Schleiermacher; Julie R Park; Dominique Valteau-Couanet; Andrew D J Pearson; Susan L Cohn
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

Review 5.  Neuroblastoma.

Authors:  John M Maris; Michael D Hogarty; Rochelle Bagatell; Susan L Cohn
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

6.  miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a.

Authors:  Xin Chen; Min Pan; Lulu Han; Hongting Lu; Xiwei Hao; Qian Dong
Journal:  FEBS Lett       Date:  2013-10-15       Impact factor: 4.124

Review 7.  The "neuro" of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder.

Authors:  Nancy Ratner; Garrett M Brodeur; Russell C Dale; Nina F Schor
Journal:  Ann Neurol       Date:  2016-04-30       Impact factor: 10.422

8.  Hypermethylation of miR-338-3p and Impact of its Suppression on Cell Metastasis Through N-Cadherin Accumulation at the Cell -Cell Junction and Degradation of MMP in Gastric Cancer.

Authors:  Bo Guo; Jing Zhang; Qian Li; Zhenghao Zhao; Wenjing Wang; Kaiyue Zhou; Xiaofei Wang; Dongdong Tong; Lingyu Zhao; Juan Yang; Chen Huang
Journal:  Cell Physiol Biochem       Date:  2018-10-11

9.  The role of EGFR/PI3K/Akt/cyclinD1 signaling pathway in acquired middle ear cholesteatoma.

Authors:  Wei Liu; Hongmiao Ren; Jihao Ren; Tuanfang Yin; Bing Hu; Shumin Xie; Yinghuan Dai; Weijing Wu; Zian Xiao; Xinming Yang; Dinghua Xie
Journal:  Mediators Inflamm       Date:  2013-11-07       Impact factor: 4.711

10.  Down-regulation of miR-338-3p and Up-regulation of MACC1 Indicated Poor Prognosis of Epithelial Ovarian Cancer Patients.

Authors:  Ruitao Zhang; Huirong Shi; Fang Ren; Zheying Liu; Pengcheng Ji; Weiwei Zhang; Wenwen Wang
Journal:  J Cancer       Date:  2019-02-23       Impact factor: 4.207

View more
  2 in total

Review 1.  Implication of microRNAs in Carcinogenesis with Emphasis on Hematological Malignancies and Clinical Translation.

Authors:  Zsuzsanna Gaál
Journal:  Int J Mol Sci       Date:  2022-05-23       Impact factor: 6.208

Review 2.  The Extracellular Matrix and Neuroblastoma Cell Communication-A Complex Interplay and Its Therapeutic Implications.

Authors:  Irena Horwacik
Journal:  Cells       Date:  2022-10-10       Impact factor: 7.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.